HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Chattanooga, Tenn. firm likely will be required to pay $20 mil.-$25 mil. to settle pending lawsuits filed against the company by consumers claiming injury related to ingestion of its Dexatrim weight loss product, which used to contain an ingredient linked to strokes, company reports May 25 during SunTrust Robinson Humphrey Institutional Investor Conference in Atlanta. However, the amount could be lower since the manufacturer of the ingredient may contribute $10 mil. under a proposed settlement. Chattem expects to confirm final settlement payout during the third quarter. As of Dec. 1, Chattem has been named as a defendant in approximately 300 lawsuits alleging injury due to ingestion of Dexatrim ingredient phenylpropanolamine (1"The Rose Sheet" Dec. 1, 2003, In Brief)...

You may also be interested in...


Interstate Fire & Casualty Company has filed a motion to "intervene as a party plaintiff" in lawsuit against Chattem previously filed in the Tennessee Eastern District Court by Kemper Indemnity Insurance Company, firm announces Nov. 26. Interstate is seeking to rescind $25 mil. of excess product liability insurance it issued to Chattem, while Kemper is attempting to withdraw $50 mil. in coverage. Interstate alleges that Chattem failed to disclose results of a Hemorrhagic Stroke Project study on phenylpropanolamine (PPA), an ingredient linked to strokes that was used in the firm's Dexatrim weight loss products until November 2000. Chattem believes both Interstate and Kemper's claims are "without merit" and vows to "aggressively" defend itself. The Chattanooga, Tenn.-based firm has been named as a defendant in approximately 300 lawsuits alleging injury due to ingestion of PPA-containing products. In May, Chattem settled a PPA suit with a Texas woman for $3 mil. plus $500,000 for certain fees and expenses...

Meitheal Introduces US Enoxaparin

Meitheal has launched enoxaparin in the US following its FDA approval towards the end of last year.

Gene Therapy For Jerry's Kids

In her new role as executive vice president, chief research officer, Sharon Hesterlee brings industry bone fides and nonprofit experiences to bear on tomorrow’s neuromuscular treatments and cures. 




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts